Skip to content

DMT research: what the evidence shows

(N,N-Dimethyltryptamine) A short-acting psychedelic studied for its acute effects on perception and its therapeutic potential.

State of the evidence

Synthesized

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for DMT, dimethyltryptamine, N,N-DMT, then ranked by relevance.

DMT is a fast-acting serotonergic psychedelic with well-replicated acute effects: dose-dependent, short-lived (peaking within minutes and resolving within ~30 minutes) alterations in perception and a profoundly altered state of consciousness, mirrored in EEG/fMRI by reduced alpha/beta power, increased signal diversity, and widespread changes in functional connectivity. It binds sigma-1 receptors and 5-HT2A receptors, shows no tolerance to its psychological effects, and appears to have low toxicity and dependence potential in ritual oral use. Clinical evidence is most developed for depression, where DMT and 5-MeO-DMT have been associated with rapid symptom reductions, but most therapeutic and mechanistic claims rest on small samples, observational or preclinical designs, and short follow-up.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator 2009 experimental study Supports DMT bound sigma-1 receptors, inhibited voltage-gated sodium channels, and induced hypermobility in wild-type but not sigma-1 knockout mice, supporting DMT as an endogenous sigma-1 agonist.
Dose-Response Study of N,N-Dimethyltryptamine in Humans 1994 double-blind, placebo-controlled RCT 12 Supports Intravenous DMT produced dose-dependent hallucinogenic effects, including vivid visual imagery and a dissociative state, beginning almost immediately, peaking at 90-120 seconds, and largely resolved by 30 minutes.
Neural correlates of the DMT experience assessed with multivariate EEG. 2019 observational cohort 13 Supports Compared with placebo, IV DMT markedly reduced alpha and beta oscillatory power and increased signal diversity, with delta and theta activity correlating with the peak of the subjective visual experience.
Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. 2020 experimental dose-response study Supports Hallucinogen potency in the mouse head-twitch response correlated strongly with reported human hallucinogenic potency (r = 0.9448, n = 36) and with rat drug-discrimination ED50 values.
Neuropharmacology of N,N-dimethyltryptamine 2016 review Mixed DMT appears to have limited neurotoxicity and adverse effects except for intense cardiovascular effects with large intravenous doses, and may be useful for treating anxiety and psychosis.
Human psychopharmacology of N,N-dimethyltryptamine 1995 dose-response and tolerance study Supports DMT produced no tolerance to its psychological effects across closely spaced doses, and pindolol pretreatment significantly increased psychological responses to DMT.
Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT 2019 cross-sectional survey 4285 Supports DMT-occasioned God encounter experiences (n = 606) closely resembled non-drug and other psychedelic-occasioned experiences and were rated among the most personally meaningful and spiritually significant lifetime experiences.
Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids 2006 systematic review Supports Oral DMT with harmala alkaloids used in religious ceremonies had a safety margin comparable to codeine, mescaline, or methadone, with minimal dependence potential and risk of sustained psychological disturbance.
DMT Models the Near-Death Experience 2018 within-subjects placebo-controlled study 13 Supports DMT administration significantly increased near-death-experience phenomenology compared with placebo, with overlap in nearly all features versus actual NDE experiencers.
Human brain effects of DMT assessed via EEG-fMRI. 2023 within-subjects placebo-controlled neuroimaging study 20 Supports A 20 mg IV bolus of DMT robustly increased global functional connectivity, disintegrated and desegregated brain networks, and compressed the principal cortical gradient, predominantly affecting transmodal association cortex.
A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. 2019 observational cohort 42 Supports A single inhalation of 5-MeO-DMT-containing toad vapor was followed by increased satisfaction with life and convergent thinking at 24 hours persisting at four weeks, increased mindfulness and decreased depression, anxiety, and stress at four weeks.
Psychological Effects of (S)-Ketamine and N,N-Dimethyltryptamine (DMT): A Double-Blind, Cross-Over Study in Healthy Volunteers 2005 double-blind crossover study 9 Mixed DMT and (S)-ketamine produced similar global psychological intensity but distinct profiles, with DMT more strongly modeling positive symptoms of schizophrenia and ketamine modeling negative symptoms and catatonia-like features.
Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. 2014 in vitro study Supports DMT and 5-MeO-DMT inhibited pro-inflammatory cytokine production and T-cell activation while increasing IL-10 via the sigma-1 receptor, indicating immunomodulatory potential.
Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by l‐tryptophan or 5‐methoxy‐N,N‐dimethyltryptamine in rats treated with a monoamine oxidase inhibitor 1971 experimental study Supports Chlorpromazine inhibited hyperactivity and hyperpyrexia produced by 5-MeO-DMT after monoamine oxidase inhibition, attributed to receptor competition or physiological antagonism.
N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function 2018 review Unclear Synthesizes evidence on DMT biosynthesis, metabolism, detection, and possible neurotransmitter role, and proposes future research to clarify its natural function in the brain.
Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Network 2026 qualitative study 4 Mixed Participants described trial procedures shaped by eligibility criteria, randomization, blinding, and fixed schedules, and extended set and setting to the clinical-trial context, generating recommendations for future trials and treatment delivery.
Ayahuasca Impairs Fear Memory Reconsolidation and Promotes Rapid Structural Plasticity in the Hippocampus and Prelimbic Cortex. 2026 preclinical experimental study Supports Ayahuasca (containing DMT) reduced freezing by impairing fear memory reconsolidation and increased dendritic spine density in hippocampal and prelimbic cortex regions without affecting adult hippocampal neurogenesis.
Pharmacological, clinical, and translational evidence for N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and zalsupindole: a systematic review. 2026 systematic review Supports Across 51 publications, clinical evidence was most developed for depression, with N,N-DMT and 5-MeO-DMT associated with rapid reductions in depressive symptoms and inhalable 5-MeO-DMT meeting its primary endpoint in a Phase 2b treatment-resistant depression trial; evidence for other conditions remained preliminary.
Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT 2026 cross-sectional survey Unclear Describes self-reported health outcomes attributed to recent use of psilocybin, LSD, MDMA, ibogaine, and 5-MeO-DMT, but no specific outcomes or effect sizes are reported in the available text.
Spiral brain dynamics track the temporal unfolding of subjective intensity during the N,N-dimethyltryptamine experience 2026 within-subject fMRI study Supports DMT increased spiral vorticity and spatial vorticity dispersion and reduced temporal irreversibility, with the largest changes in default mode, visual, frontoparietal, and dorsal attention networks and the strongest reorganization during offset and recovery.
N,N-Dimethyltryptamine and harmine formulation alters transient EEG topography sequences near the peak of the psychedelic state 2026 randomized controlled trial 25 Supports A DMT/harmine formulation reduced EEG microstate duration but increased microstate occurrence and complexity and made transition sequences less random compared with harmine alone and placebo.
Toxicokinetics and analytical toxicology of four N, N-dimethyltryptamine derivatives studied in human in vitro systems and in vivo by means of zebrafish embryos. 2026 in vitro and in vivo metabolism study Unclear Four DMT derivatives were extensively metabolized mainly via N-demethylation and hydroxylation, with CYP1A2, CYP2D6, and FMO3 most active and in vitro half-lives of 74 to over 180 minutes and plasma protein binding above 99 percent.
Defining the Intervention Before Estimating Efficacy in DMT-Assisted Therapy (Accepted Manuscript) 2026 commentary Unclear Argues that DMT-assisted therapy for substance misuse should be evaluated as a complex intervention distinguishing pharmacological exposure, psychological integration, contextual elements, and safety safeguards.
515. Influence of the context of administration on 5-MeO-DMT-promoted antidepressant-like effects and neuroplasticity 2026 preclinical experimental study Mixed 5-MeO-DMT at 0.5 mg/kg produced antidepressant-like effects in neutral or positive settings but not in a negative setting, which instead promoted anxiogenic-like responses, with positive setting linked to perineuronal net degradation around hippocampal parvalbumin interneurons.
188. A single high-dose acute injection of 5-MeO-DMT reverses stress-induced anhedonia in rats 2026 preclinical experimental study Supports A single 10 mg/kg dose of 5-MeO-DMT reversed chronic-mild-stress-induced anhedonia and normalized REM sleep reductions, while vehicle-treated stressed rats remained anhedonic.

Points of agreement

  • DMT produces rapid, dose-dependent psychedelic effects that peak within minutes and largely resolve within 20-30 minutes.
  • DMT acts on 5-HT2A receptors and also binds sigma-1 receptors, with sigma-1 mediating immunomodulatory and behavioral effects.
  • Neuroimaging and EEG consistently show reduced alpha/beta oscillatory power, increased signal diversity, and widespread increases in functional connectivity and network reorganization.
  • Ritual oral DMT (ayahuasca) appears to have low toxicity and minimal dependence potential, with transient aversive reactions resolving spontaneously.
  • Clinical and preclinical evidence points toward rapid antidepressant effects of DMT and 5-MeO-DMT, with depression the most developed indication.
  • DMT does not induce tolerance to its psychological effects, unlike other classic hallucinogens.

Conflicts

  • Pindolol pretreatment increased DMT responses in humans, which the authors note is opposite to findings in lower animal models of hallucinogen mechanisms.
  • 5-MeO-DMT produced antidepressant-like effects in neutral or positive settings but anxiogenic-like effects in a negative setting, indicating context can reverse the direction of behavioral outcomes.
  • DMT models positive symptoms of schizophrenia while ketamine models negative symptoms, so neither drug class is clearly the superior psychosis model.

Gaps

  • Most human studies have very small samples (9-25 participants) and short follow-up, limiting durability and generalizability.
  • Blinding integrity in psychedelic trials is questioned by participant accounts, and expectancy effects are not well controlled.
  • The natural physiological role of endogenous DMT remains unresolved.
  • Clinical evidence for indications other than depression (substance use disorders, PTSD, eating disorders) is preliminary.
  • Whether neuroplasticity-promoting effects can be separated from hallucinogenic effects is unknown.
  • Little human data on repeated dosing, long-term safety, and cardiovascular effects of large intravenous doses.
Browse these studies in the library

Common questions

What does the research agree on about DMT?
  • DMT produces rapid, dose-dependent psychedelic effects that peak within minutes and largely resolve within 20-30 minutes.
  • DMT acts on 5-HT2A receptors and also binds sigma-1 receptors, with sigma-1 mediating immunomodulatory and behavioral effects.
  • Neuroimaging and EEG consistently show reduced alpha/beta oscillatory power, increased signal diversity, and widespread increases in functional connectivity and network reorganization.
  • Ritual oral DMT (ayahuasca) appears to have low toxicity and minimal dependence potential, with transient aversive reactions resolving spontaneously.
  • Clinical and preclinical evidence points toward rapid antidepressant effects of DMT and 5-MeO-DMT, with depression the most developed indication.
  • DMT does not induce tolerance to its psychological effects, unlike other classic hallucinogens.
Where do studies on DMT conflict?
  • Pindolol pretreatment increased DMT responses in humans, which the authors note is opposite to findings in lower animal models of hallucinogen mechanisms.
  • 5-MeO-DMT produced antidepressant-like effects in neutral or positive settings but anxiogenic-like effects in a negative setting, indicating context can reverse the direction of behavioral outcomes.
  • DMT models positive symptoms of schizophrenia while ketamine models negative symptoms, so neither drug class is clearly the superior psychosis model.
What is still unknown about DMT?
  • Most human studies have very small samples (9-25 participants) and short follow-up, limiting durability and generalizability.
  • Blinding integrity in psychedelic trials is questioned by participant accounts, and expectancy effects are not well controlled.
  • The natural physiological role of endogenous DMT remains unresolved.
  • Clinical evidence for indications other than depression (substance use disorders, PTSD, eating disorders) is preliminary.
  • Whether neuroplasticity-promoting effects can be separated from hallucinogenic effects is unknown.
  • Little human data on repeated dosing, long-term safety, and cardiovascular effects of large intravenous doses.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is DMT, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when DMT or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: September 2026 →

1,593 articles · 494 from the last two years · 3,192,671 participants across 424 studies reporting sample size

Common study designs

review 302 systematic review 69 experimental study 201 observational study 53 theoretical or philosophical paper 106

Research volume by year

Compare topics →

509 studies whose primary subject is DMT since 2002

Studies about DMT per year, 2002 to 2026, peaking at 102 in 2025 Bar chart: one bar per year, taller where more studies were published that year. 0 100 200 2005 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about DMT per year, 2002 to 2026, peaking at 102 in 2025
Year Studies
2002 1
2003 3
2004 0
2005 7
2006 5
2007 3
2008 3
2009 10
2010 4
2011 6
2012 8
2013 6
2014 9
2015 5
2016 9
2017 12
2018 19
2019 17
2020 21
2021 16
2022 34
2023 56
2024 60
2025 102
2026 93

Research

Synthesize the evidence → Search all →

Title: DMT, Salvinorin A, and Stress Regulation: An Exploratory Neuropharmacological Research Proposal

Zenodo (CERN European Organization for Nuclear Research) October 21, 2026 Peter McGrath preprint

Title: DMT, Salvinorin A, and Stress Regulation: An Exploratory Neuropharmacological Research Proposal Creator: Peter McGrath Affiliation: Appalachian State University Resource type: Publication — Working Paper Description: This independent undergraduate research proposal examines differences between the serotonergic mechanisms of N,N-DMT and the kappa-opioid receptor activity of salvinorin A,...

DOI: 10.5281/zenodo.23540286 (opens in new tab)

Is the Prostate a Site of Endogenous DMT Synthesis? A Testable Hypothesis

Zenodo (CERN European Organization for Nuclear Research) October 21, 2026 Shannon Green preprint

Endogenous N,N-dimethyltryptamine (DMT) has been detected in mammals, but its physiological functions and the distribution of functionally relevant synthesis remain unresolved. This paper proposes prostatic tissue as a candidate peripheral site of synthesis. Oncology studies document indolethylamine N-methyltransferase (INMT) expression in human prostate samples, including adjacent...

DOI: 10.5281/zenodo.23534361 (opens in new tab)

Analytical characterization of novel psychoactive substances and adulterants: ortho-methyl fentanyl, N,N-dimethyltryptamine, and medetomidine

TUScholarShare October 19, 2026 Sara E Walton

Forensic toxicology relies heavily on foundational analytical chemistry techniques for the identification and characterization of drugs and toxins, and this work specifically focused on novel psychoactive substances (NPS). NPS are drugs that have newly emerged on the illicit or recreational drug market for use that circumvents legislation (i.e., “legal highs”) and cause significant risk to drug...

DOI: 10.34944/22br-ry12 (opens in new tab)

Pharmacological, clinical, and translational evidence for N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and zalsupindole: a systematic review.

Progress in neuro-psychopharmacology & biological psychiatry October 6, 2026 Chad Collyer, Gia Han Le, Maryam Hassan et al.

Short-acting tryptamine psychedelics are emerging as candidate psychiatric therapeutics with pharmacological profiles that may offer practical advantages over longer-acting psychedelics. N,N-dimethyltryptamine (N,N-DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) differ in pharmacokinetic, receptor, and phenomenological properties, while zalsupindole is a putatively non-hallucinogenic...

DOI: 10.1016/j.pnpbp.2026.111966 (opens in new tab) Full text (opens in new tab) 5-MEO-DMT N,N-DMT Pharmacodynamics Pharmacokinetics +1

Synthesis of 1,2,3‐Triazole Derivatives of N , N ‐Dimethyltryptamine Isolated From Mimosa tenuiflora Root Bark: Antiplasmodial Activity In Silico and In Vitro

Chemistry & Biodiversity October 1, 2026 Renato Pinto de Sousa, William Cezar de Lima Silva, Caíque Lopes Duarte et al.

ABSTRACT: Malaria is a severe parasitic disease, with Plasmodium falciparum as one of the main etiological agents. The growing resistance to antimalarial drugs underscores the urgent need for the development of new therapeutic agents. This study describes the semisynthesis of eight new 1,4‐disubstituted 1,2,3‐triazole derivatives ( 3–10 ) from N , N ‐dimethyltryptamine ( 1 ), isolated from...

DOI: 10.1002/cbdv.71849 (opens in new tab)

Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT

JAMA Network Open September 29, 2026 Otto Simonsson, Melissa Bradley, Joshua Curtis Black et al.

This cross-sectional study describes health outcomes attributed to recent use of psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a nationally representative survey of US adults.

DOI: 10.1001/jamanetworkopen.2026.36756 (opens in new tab)

Spiral brain dynamics track the temporal unfolding of subjective intensity during the N,N-dimethyltryptamine experience

bioRxiv (Cold Spring Harbor Laboratory) September 28, 2026 Gabriela Sawicka, Marian Martínez-Marín, Christopher Timmermann et al. preprint

Psychedelic compounds such as N,N-dimethyltryptamine (DMT) induce rapid and profound changes in conscious experience, requiring neuroimaging measures that capture how brain dynamics evolve across space and time. Emerging evidence suggests that rotational (vortex-like) dynamics may contribute to the coordination of large-scale neural activity. Here, we introduce two vorticity-based metrics;...

DOI: 10.64898/2026.09.22.753116 (opens in new tab)

N,N-Dimethyltryptamine and harmine formulation alters transient EEG topography sequences near the peak of the psychedelic state

Journal of Psychopharmacology September 22, 2026 Maria Niedernhuber, Dila Suay, Bigna Lenggenhager et al.

BACKGROUND: Psychoactive serotonin 5-HT2A receptor agonists are potent modulators of awareness. Influential theories propose that psychedelics alter whole-brain dynamics by increasing neural signal diversity and dynamic flexibility. Beyond temporal variability, it is an open question whether psychedelics impact the characteristics of transient neural state sequences themselves. AIMS: Our goal...

DOI: 10.1177/02698811261481062 (opens in new tab)

Toxicokinetics and analytical toxicology of four N, N-dimethyltryptamine derivatives studied in human in vitro systems and in vivo by means of zebrafish embryos.

Archives of Toxicology September 21, 2026 Gloria Daziani, Lea Wagmann, Matthias D. Kroesen et al.

N,N-Dimethyltryptamine (DMT) is a naturally occurring substituted tryptamine used as a psychedelic drug for ritual purposes by various cultures. Derivatives were already found on the drug of abuse market, such as N1-tert-butoxycarbonyl-N,N-dimethyltryptamine (DMT-Boc). The aim of the current study was to investigate the toxicokinetics of DMT-Boc and three related DMT derivatives, by name...

DOI: 10.1007/s00204-026-04552-3 (opens in new tab) Full text (opens in new tab) Metabolism New psychoactive substances Toxicokinetics Tryptamines

Defining the Intervention Before Estimating Efficacy in DMT-Assisted Therapy (Accepted Manuscript)

Zenodo (CERN European Organization for Nuclear Research) September 18, 2026 Kenjiro Shiraishi preprint

Accepted manuscript of:Shiraishi K. Defining the Intervention Before Estimating Efficacy in DMT-Assisted Therapy. Journal of Psychopharmacology. 2026.DOI: 10.1177/02698811261488484 This Letter argues that DMT-assisted therapy for substance misuse should be evaluated as a complex intervention rather than as pharmacological exposure alone. It highlights the need to distinguish pharmacological...

DOI: 10.5281/zenodo.22821320 (opens in new tab)

Clinical trials

All DMT trials →